Moderna Stock Trending Down Despite Vaccine Approval | $MRNA Stock Analysis

TL;DR

Moderna, a company known for its COVID-19 vaccine, has seen significant stock growth and market attention. However, its financials raise concerns about overvaluation and sustainability.

Transcript

hey everybody welcome to the everything money show it's uncle paul and seth we uh welcome you into uh our analysis of companies paul today we are looking at moderna obviously this is huge in the news their vaccine is rolling out the rna attack on your cells uh and uh we did a fizer video last week which uh completely exploded but what we really wan... Read More

Key Insights

• 🤨 Moderna's stock price growth is primarily based on the success of its COVID-19 vaccine, but its financials raise concerns about overvaluation.
• 😘 The company's revenue is significantly lower than its market capitalization, indicating a potential disconnect between stock price and actual financial performance.
• 🌸 Moderna's consistent losses and negative profit margin highlight the riskiness of investing in the company.
• 🥶 Dilution of shares and the lack of consistent free cash flow further exacerbate concerns about the company's financial stability.
• ❓ Investors should closely monitor Moderna's future financial performance and diversify their investments rather than solely relying on the vaccine giant.
• 🍉 The qualitative aspect of evaluating Moderna's long-term potential should also be considered, including its pipeline of drugs beyond the COVID-19 vaccine.
• 🔨 Those interested in comprehensive financial analysis like Moderna's should consider becoming a patron on Everything Money's Patreon platform for access to valuable tools and insights.

Questions & Answers

Q: Why is Moderna receiving so much attention in the stock market?

Moderna's stock has gained attention due to its successful COVID-19 vaccine and the potential for future growth. The market is excited about the company's prospects.

Q: Is Moderna a healthy company to invest in?

Financially, Moderna's revenue is relatively low compared to its market capitalization, and it has consistently been losing money. This raises concerns about its long-term prospects as an investment.

Q: Are the fundamentals of a company more important than its stock price?

For value investors, fundamentals are crucial. In the long run, a company's financial health and growth potential drive its stock price, not just short-term popularity or hype.

Q: How does Moderna's price-to-sales ratio compare to other companies?

Moderna's price-to-sales ratio is 192, way above the median of 2.6 for the top 3,000 companies. This suggests that the stock is overpriced compared to its revenue.

Summary & Key Takeaways

• Moderna's stock price has soared since its IPO in December 2018, driven by the success of its COVID-19 vaccine.

• Despite its high market capitalization of $51 billion, Moderna's revenue in the past 12 months is only $245 million.

• The company's negative profit margin and consistent losses in the past five years raise doubts about its long-term profitability.